100 related articles for article (PubMed ID: 29844366)
21. E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma.
Bertonnier-Brouty L; Andersson J; Kaprio T; Hagström J; Bsharat S; Asplund O; Hatem G; Haglund C; Seppänen H; Prasad RB; Artner I
Cancer Med; 2024 May; 13(9):e7187. PubMed ID: 38686617
[TBL] [Abstract][Full Text] [Related]
22. Expression patterns of E2Fs identify tumor microenvironment features in human gastric cancer.
Li F; Yan J; Leng J; Yu T; Zhou H; Liu C; Huang W; Sun Q; Zhao W
PeerJ; 2024; 12():e16911. PubMed ID: 38371373
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide ATAC-see screening identifies TFDP1 as a modulator of global chromatin accessibility.
Ishii S; Kakizuka T; Park SJ; Tagawa A; Sanbo C; Tanabe H; Ohkawa Y; Nakanishi M; Nakai K; Miyanari Y
Nat Genet; 2024 Mar; 56(3):473-482. PubMed ID: 38361031
[TBL] [Abstract][Full Text] [Related]
24. A Nucleotide Metabolism-Related Gene Signature for Risk Stratification and Prognosis Prediction in Hepatocellular Carcinoma Based on an Integrated Transcriptomics and Metabolomics Approach.
Wei T; Liu J; Ma S; Wang M; Yuan Q; Huang A; Wu Z; Shang D; Yin P
Metabolites; 2023 Oct; 13(11):. PubMed ID: 37999212
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations.
Färber B; Lapshyna O; Künstner A; Kohl M; Sauer T; Bichmann K; Heckelmann B; Watzelt J; Honselmann K; Bolm L; Ten Winkel M; Busch H; Ungefroren H; Keck T; Gemoll T; Wellner UF; Braun R
Front Oncol; 2023; 13():1230382. PubMed ID: 37719017
[TBL] [Abstract][Full Text] [Related]
26. Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma.
Gai Y; Qian L; Jiang S; Li J; Zhang X; Yang X; Pan H; Liao Y; Wang H; Huang S; Zhang S; Nie H; Ma M; Li H
Funct Integr Genomics; 2023 Mar; 23(2):90. PubMed ID: 36933061
[TBL] [Abstract][Full Text] [Related]
27. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
Nakajima R; Zhao L; Zhou Y; Shirasawa M; Uchida A; Murakawa H; Fikriyanti M; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833320
[TBL] [Abstract][Full Text] [Related]
28. Targeting E2F Sensitizes Prostate Cancer Cells to Drug-Induced Replication Stress by Promoting Unscheduled CDK1 Activity.
Hamidi M; Eriz A; Mitxelena J; Fernandez-Ares L; Aurrekoetxea I; Aspichueta P; Iglesias-Ara A; Zubiaga AM
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230876
[TBL] [Abstract][Full Text] [Related]
29. Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma.
Luo H; Tao C; Long X; Zhu X; Huang K
Bioengineered; 2021 Dec; 12(1):7765-7779. PubMed ID: 34617871
[TBL] [Abstract][Full Text] [Related]
30. Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy.
Zhang X; Wei C; Liang H; Han L
Front Oncol; 2021; 11():587554. PubMed ID: 33777739
[TBL] [Abstract][Full Text] [Related]
31. Transcription Factors in Cancer Development and Therapy.
Vishnoi K; Viswakarma N; Rana A; Rana B
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824207
[TBL] [Abstract][Full Text] [Related]
32. Integrated analysis of the E2F transcription factors across cancer types.
Wang H; Wang X; Xu L; Zhang J; Cao H
Oncol Rep; 2020 Apr; 43(4):1133-1146. PubMed ID: 32323836
[TBL] [Abstract][Full Text] [Related]
33. Expression and prognostic role of E2F transcription factors in high-grade glioma.
Yu H; Li Z; Wang M
CNS Neurosci Ther; 2020 Jul; 26(7):741-753. PubMed ID: 32064771
[TBL] [Abstract][Full Text] [Related]
34. Next-generation RNA sequencing of FFPE subsections reveals highly conserved stromal reprogramming between canine and human mammary carcinoma.
Amini P; Nassiri S; Ettlin J; Malbon A; Markkanen E
Dis Model Mech; 2019 Aug; 12(8):. PubMed ID: 31308057
[TBL] [Abstract][Full Text] [Related]
35. The broken cycle: E2F dysfunction in cancer.
Kent LN; Leone G
Nat Rev Cancer; 2019 Jun; 19(6):326-338. PubMed ID: 31053804
[TBL] [Abstract][Full Text] [Related]
36. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.
Lan W; Bian B; Xia Y; Dou S; Gayet O; Bigonnet M; Santofimia-Castaño P; Cong M; Peng L; Dusetti N; Iovanna J
Sci Rep; 2018 May; 8(1):8330. PubMed ID: 29844366
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
38. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
39. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Witkiewicz AK; Balaji U; Eslinger C; McMillan E; Conway W; Posner B; Mills GB; O'Reilly EM; Knudsen ES
Cell Rep; 2016 Aug; 16(7):2017-31. PubMed ID: 27498862
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
